Akari Therapeutics to Present at 2026 Biocom Global Partnering & Investor Conference

Reuters

Feb 18

Akari <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Present at 2026 Biocom Global Partnering & Investor Conference

Akari Therapeutics plc (Nasdaq: AKTX) announced that its President and CEO, Abizer Gaslightwala, will present in person at the 2026 Biocom Global Partnering & Investor Conference on Wednesday, February 25, 2026 at 11:00 AM PST (Track B) in San Diego. Event details and registration information are available via the conference listing and website: https://www.globenewswire.com/Tracker?data=xQ6Th0oR_u23fAjBdo-UGZFH_tltgFndFe8oBz24RzxTwMsAV5OSCOv8E42itPvKAxEchGRzqeksrBkj5DWun7Vcz4IgBK07coBmhEmm9-1fi-ZoJ3h3DnBBYDRyKhjjGEY9DqRuVhVtp4WRXC1GhbNKyeySbC1yhUSaLadn2prqdGFc3Wf6LoXfBBpSM14pvHNoQsWHjx89e2g6V4resg== and https://www.globenewswire.com/Tracker?data=iBrWh-pJWqulUBn41uZ9jSf2jxYm1WE38WnOUgJw68CyW0x8Xh_MyIxgOV4Z_E443w1BAkZGMEdYxuXo4n-E_7N8uLPil5tkuCGKgroQqmBWWULspm4UzkqgxO4Xk7V3FqUpyJ0hEnLMTOVkPSMh7w==.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9656507-en) on February 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612494824"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612494824\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612494824?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612494824","market":"nz","top_or_hot":-1,"title":"Akari Therapeutics to Present at 2026 Biocom Global Partnering & Investor Conference","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akari <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present at 2026 Biocom Global Partnering &amp; Investor Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akari Therapeutics plc (Nasdaq: AKTX) announced that its President and CEO, Abizer Gaslightwala, will present in person at the 2026 Biocom Global Partnering &amp; Investor Conference on Wednesday, February 25, 2026 at 11:00 AM PST (Track B) in San Diego. Event details and registration information are available via the conference listing and website: https://www.globenewswire.com/Tracker?data=xQ6Th0oR_u23fAjBdo-UGZFH_tltgFndFe8oBz24RzxTwMsAV5OSCOv8E42itPvKAxEchGRzqeksrBkj5DWun7Vcz4IgBK07coBmhEmm9-1fi-ZoJ3h3DnBBYDRyKhjjGEY9DqRuVhVtp4WRXC1GhbNKyeySbC1yhUSaLadn2prqdGFc3Wf6LoXfBBpSM14pvHNoQsWHjx89e2g6V4resg== and https://www.globenewswire.com/Tracker?data=iBrWh-pJWqulUBn41uZ9jSf2jxYm1WE38WnOUgJw68CyW0x8Xh_MyIxgOV4Z_E443w1BAkZGMEdYxuXo4n-E_7N8uLPil5tkuCGKgroQqmBWWULspm4UzkqgxO4Xk7V3FqUpyJ0hEnLMTOVkPSMh7w==.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9656507-en) on February 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akari Therapeutics to Present at 2026 Biocom Global Partnering & Investor Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkari Therapeutics to Present at 2026 Biocom Global Partnering & Investor Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-18 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akari <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present at 2026 Biocom Global Partnering &amp; Investor Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akari Therapeutics plc (Nasdaq: AKTX) announced that its President and CEO, Abizer Gaslightwala, will present in person at the 2026 Biocom Global Partnering &amp; Investor Conference on Wednesday, February 25, 2026 at 11:00 AM PST (Track B) in San Diego. Event details and registration information are available via the conference listing and website: https://www.globenewswire.com/Tracker?data=xQ6Th0oR_u23fAjBdo-UGZFH_tltgFndFe8oBz24RzxTwMsAV5OSCOv8E42itPvKAxEchGRzqeksrBkj5DWun7Vcz4IgBK07coBmhEmm9-1fi-ZoJ3h3DnBBYDRyKhjjGEY9DqRuVhVtp4WRXC1GhbNKyeySbC1yhUSaLadn2prqdGFc3Wf6LoXfBBpSM14pvHNoQsWHjx89e2g6V4resg== and https://www.globenewswire.com/Tracker?data=iBrWh-pJWqulUBn41uZ9jSf2jxYm1WE38WnOUgJw68CyW0x8Xh_MyIxgOV4Z_E443w1BAkZGMEdYxuXo4n-E_7N8uLPil5tkuCGKgroQqmBWWULspm4UzkqgxO4Xk7V3FqUpyJ0hEnLMTOVkPSMh7w==.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9656507-en) on February 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDLhpGzl:1","article_id":"2612494824","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612494824","pubTimestamp":1771423516,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire  on February 18, 2026, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4139":"生物科技","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","AKTX":"Akari Therapeutics PLC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","BK4112":"金融交易所和数据"},"translate_title":"Akari Therapeutics将出席2026年Biocom全球合作与投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKTX":0.9,"NDAQ":0.9},"content_text":"Akari Therapeutics to Present at 2026 Biocom Global Partnering & Investor Conference\n    \n\n        Akari Therapeutics plc (Nasdaq: AKTX) announced that its President and CEO, Abizer Gaslightwala, will present in person at the 2026 Biocom Global Partnering & Investor Conference on Wednesday, February 25, 2026 at 11:00 AM PST (Track B) in San Diego. Event details and registration information are available via the conference listing and website: https://www.globenewswire.com/Tracker?data=xQ6Th0oR_u23fAjBdo-UGZFH_tltgFndFe8oBz24RzxTwMsAV5OSCOv8E42itPvKAxEchGRzqeksrBkj5DWun7Vcz4IgBK07coBmhEmm9-1fi-ZoJ3h3DnBBYDRyKhjjGEY9DqRuVhVtp4WRXC1GhbNKyeySbC1yhUSaLadn2prqdGFc3Wf6LoXfBBpSM14pvHNoQsWHjx89e2g6V4resg== and https://www.globenewswire.com/Tracker?data=iBrWh-pJWqulUBn41uZ9jSf2jxYm1WE38WnOUgJw68CyW0x8Xh_MyIxgOV4Z_E443w1BAkZGMEdYxuXo4n-E_7N8uLPil5tkuCGKgroQqmBWWULspm4UzkqgxO4Xk7V3FqUpyJ0hEnLMTOVkPSMh7w==.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9656507-en) on February 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}